ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection

Ark Biopharmaceutical Co., Ltd. announced the completion of patient enrollment and dosing of ziresovir for the treatment of respiratory syncytial virus infection in a Phase III registration clinical trial.